Important Info
The position is available immediately. To apply for this position, please submit a complete CV along with the names of 3 referees via E-mail to: yej1@stanford.edu
The Department of Radiation Oncology and Biology at Stanford University is seeking a highly motivated postdoctoral candidate to investigate how metabolic reprogramming regulates chromatin remodeling in cancer progression using metabolomic and epigenetic tools.
A hallmark of cancer is the alteration of metabolic pathways, which reshapes the epigenetic landscape and impedes cell differentiation. Dr. Jiangbin Ye's primary focus lies in examining the origins and implications of these abnormal metabolic traits in tumor cells. He envisions that metabolic intervention strategies could be devised to recalibrate these pathways, enhancing differentiation therapy. The lab's current objectives include:
- Investigating the intricate interplay between metabolic reprogramming and epigenetic regulations, and understanding how these epigenetic shifts govern cell fate and the differentiation process.
- Identifying specific metabolites from patient samples that serve as biomarkers for early cancer detection and diagnosis.
Ye's lab is situated within the Stanford University School of Medicine, equipped with state-of-the-art research facilities. The interdisciplinary research setting offers unparalleled training and collaboration opportunities. The selected candidate will benefit from immediate access to cutting-edge metabolomics research instruments, including the YSI Biochemical Analyzer, Seahorse XF Analyzer, Hypoxia Chamber, and Agilent Q-TOF LC-MS. The lab excels in both untargeted and targeted metabolomics analysis, with a notable expertise in the isotope tracing technique for metabolic flux analysis. Dr. Ye is deeply committed to mentoring and training the selected individual, ensuring comprehensive support to achieve their career aspirations.
- Previous experience in LC-MS metabolomics research and/or next-generation sequencing is highly desirable. Candidates with significant expertise in Agilent Q-TOF or similar LC-MS models will be prioritized.
- A Ph.D. or equivalent in biochemistry, cancer research, or a related biomedical research field is required. A robust history of peer-reviewed publications is essential.
- Applicants should possess the capability to acquire and master new skills, particularly mass spectrometry techniques relevant to the studies. Familiarity with prevalent bioinformatic and biostatistical analysis tools is a plus.
- Complete CV
- Names of 3 referees